November 16, 2011 — MedSolutions announced the launch of its Implantable Cardioverter Defibrillator (ICD) Surgery Management Program. The system uses evidence-based guidelines to ensure the clinical appropriateness of ICD and cardiac resynchronization therapy defibrillator (CRT-D) implantation and directs members to the most qualified physicians and facilities.

November 16, 2011 — The American Society of Echocardiography (ASE) issued a response voicing concerns over the implications of a study published this week in the Journal of the American Medical Association (JAMA).

November 16, 2011 – BSP Biological Signal Processing, which develops and manufactures products for the non-invasive, accurate diagnosis of coronary artery disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company’s HyperQ technology in diagnosing CAD. An article describing the study and its results was accepted for publication in the American Journal of Cardiology.

 

November 16, 2011 — Heart failure patients with a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that infused them with their own stem cells. The results triple the 4 percent improvement average the researchers projected for the Phase I trial.

November 16, 2011 – Cambridge Consultants unveiled how it has collaborated with start-up company EBR Systems to develop the world’s first wireless pacing system.

November 16, 2011 – Johnson & Johnson Pharmaceutical Research & Development announced that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular-related deaths, heart attacks or strokes in patients with acute coronary syndrome (ACS) compared to those receiving standard therapy alone. Results from the pivotal Phase 3 ATLAS ACS 2 TIMI 51 trial presented at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine also showed that rivaroxaban significantly increased rates of major bleeding, but did not create an excess risk of fatal bleeding over standard therapy alone.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now